We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Biomedica Licenses its Gene Delivery Technology to Virxsys
News

Oxford Biomedica Licenses its Gene Delivery Technology to Virxsys

Oxford Biomedica Licenses its Gene Delivery Technology to Virxsys
News

Oxford Biomedica Licenses its Gene Delivery Technology to Virxsys

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Biomedica Licenses its Gene Delivery Technology to Virxsys"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford BioMedica and Virxsys Corporation have announced a licence agreement for Oxford BioMedica’s VSV-G viral envelope technology for gene delivery.

The agreement provides Virxsys with rights to utilise this technology in the production process of Virxsys’s anti-HIV/AIDS product VRX496 which is currently in Phase II trials.

Under the agreement, Oxford BioMedica receives an upfront licence fee and annual maintenance payments.

In addition, Oxford BioMedica will receive payments on the achievement of clinical and regulatory milestones by Virxsys and product royalties.

Oxford BioMedica’s CEO, Professor Alan Kingsman, said, "We are delighted to welcome Virxsys to the growing list of Oxford BioMedica’s technology licensees. This agreement further underlines the breadth and strength of our proprietary gene delivery technologies."

Advertisement